32 results
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
27 Sep 24
Quantum Biopharma Provides Corporate Update
8:09pm
and with either party having the right to terminate the engagement agreement upon providing ten days' notice. The cost of the engagement is US$35,000 … to terminate the engagement agreement upon providing ten days' notice. The cost of the engagement is US$75,000USD and will start October 7, 2024. The terms
6-K
EX-4.1
QNTM
Quantum BioPharma Ltd
26 Aug 24
Current report (foreign)
6:04pm
.
Process Authority forms for engagement (Diebel Laboratories).
Final product specs (for F2R5, with sucralose content (%w/w) revised to 0.03%; called
6-K/A
EX-99.2
QNTM
Quantum BioPharma Ltd
19 Aug 24
Condensed consolidated interim financial statements
5:18pm
. Totaligent has been engaged for a 30-day term, with either party having the right to terminate the engagement agreement upon providing 5 business day
6-K
EX-99.2
QNTM
Quantum BioPharma Ltd
14 Aug 24
Condensed consolidated interim financial statements
6:13am
. Totaligent has been engaged for a 30-day term, with either party having the right to terminate the engagement agreement upon providing 5 business day
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
29 Jul 24
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
9:04pm
benefits and fulfill the terms of the engagement with Totaligent. Accordingly, readers should not place undue reliance on the forward-looking statements … and fulfill the terms of the engagement with Totaligent. Accordingly, readers should not place undue reliance on the forward-looking statements
6-K
EX-99.1
p0t0f
8 Jul 24
Annual General and Special Meeting of the Shareholders to Be Held on Management Information Circular
5:16pm
6-K
EX-99.1
ey8q6xy7
28 Jun 24
FSD Pharma provides Corporate Update
5:01pm
6-K
EX-10.1
jtr61rxk6ou9
20 Feb 24
FSD Pharma Announces US ATM Offering
6:01am
6-K
EX-99.1
m83qswif
7 Feb 24
FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
4:03pm
6-K
EX-99.1
z3k1u
23 May 22
Annual General Meeting of the Shareholders
4:29pm
6-K
lyq1mn8
2 May 22
FSD Pharma Inc. Form 6-K
6:01am
6-K
EX-99.1
qb0b k2l9
2 May 22
FSD Pharma Inc. Form 6-K
6:01am
20-F
6caaemg
31 Mar 22
Annual report (foreign)
8:09am
6-K
EX-99.1
kdvp9mtx
23 Sep 21
FSD Pharma Inc. Form 6-K
7:21am
6-K
0y50vqb0126xn
23 Sep 21
FSD Pharma Inc. Form 6-K
7:21am
6-K
EX-99.1
x61w7p ug2z
21 Sep 21
THIS AGREEMENT made as of the 25th day of August, 2021
4:02pm
40-F
EX-99.1
a671lyhscm 6tykiv
17 Mar 21
Annual report (Canada)
12:00am
SUPPL
3yvewvuzxkchd7z9xa
11 Feb 21
Supplemental materials (foreign)
8:32am
6-K
EX-99.2
j02x2u
16 Oct 20
FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering
5:21pm